Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 11 - Drugs for disorders of the respiratory system
Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
04/2003
04/04/2003WO2002030390A2 Method for producing powdery formulations
04/03/2003WO2003027263A2 Proteins associated with cell growth, differentiation, and death
04/03/2003WO2003027248A2 Antibody inhibitors of gdf-8 and uses thereof
04/03/2003WO2003027234A2 Small organic molecule regulators of cell proliferation
04/03/2003WO2003027114A1 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
04/03/2003WO2003027076A2 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity
04/03/2003WO2003027075A2 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
04/03/2003WO2003026669A1 Monobactam antibacterial compounds and methods of use thereof
04/03/2003WO2003026660A1 An enantiomerically pure diarylmethylpiperazine and methods of using same
04/03/2003WO2003026648A1 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
04/03/2003WO2003026647A1 Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
04/03/2003WO2003026630A1 Dosage forms having an inner core and outer shell with different shapes
04/03/2003WO2003026629A2 Modified release dosage forms
04/03/2003WO2003026628A2 Composite dosage forms having an inlaid portion
04/03/2003WO2003026627A1 Composite dosage forms
04/03/2003WO2003026626A2 Modified release dosage forms
04/03/2003WO2003026625A1 Modified release dosage forms
04/03/2003WO2003026624A1 Modified release dosage forms
04/03/2003WO2003026616A1 Edible composition and dosage form comprising an edible shell
04/03/2003WO2003026615A2 Modified release dosage forms
04/03/2003WO2003026614A1 Dosage form containing a confectionery composition
04/03/2003WO2003026613A1 Fondant-based pharmaceutical composition
04/03/2003WO2003026612A2 Dosage forms having an inner core and outer shell
04/03/2003WO2003026579A2 Combination therapies for immune mediated diseases
04/03/2003WO2003026430A1 Treatment of allergic rhinitis
04/03/2003WO2003002722A3 T cell regulatory genes and methods of use thereof
04/03/2003WO2003002530A3 Pyrrolidines as dipeptidyl peptidase inhibitors
04/03/2003WO2002102313A3 Pyrimidine inhibitors of phosphodiesterase (pde) 7
04/03/2003WO2002100332A3 Isoxazoline compounds having mif antagonist activity
04/03/2003WO2002085338A3 Ipratropium formulation for pulmonary inhalation
04/03/2003WO2002085296A3 Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
04/03/2003WO2002070559A3 Nuclear hormone receptor ligand binding domains
04/03/2003WO2002014369A9 Human kininogen d5 domain polypeptides and their use
04/03/2003WO2002000860A3 Novel proteases
04/03/2003US20030065174 Antiinflammatory agents; analgesics
04/03/2003US20030065007 Analgesics; psychological disorders; antidepressants
04/03/2003US20030064999 Therapy for asthma, diarrhea
04/03/2003US20030064987 Immunology moderators; interleukin antagonist; anticancer agents
04/03/2003US20030064983 Headaches; antiarthritic agents; respiratory system disorders; psychological disorders
04/03/2003US20030064952 Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
04/03/2003US20030064932 Methods of treatment comprising administration of Substance P
04/03/2003US20030064114 For vasodilatation and inhibition of transplant rejection
04/03/2003US20030064098 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
04/03/2003US20030064094 Agent for treating illnesses of the tracheobronchial tract, especially chronic obstructive pulmonary disease (COPD)
04/03/2003US20030064069 Specific binding members for TGFbeta1
04/03/2003US20030064063 For prophylaxis of type I hypersensitivity disease in a subject receiving immunotherapy
04/03/2003US20030064029 Use of a bioactive agent in manufacture of a medicament for pulmonary delivery whereby medicament comprises perforated microstructures which are aerosolized using an inhalation device to provide aerosolized medicament
04/03/2003CA2469230A1 Antibody inhibitors of gdf-8 and uses thereof
04/03/2003CA2461903A1 Monobactam antibacterial compounds and methods of use thereof
04/03/2003CA2461870A1 Modified release dosage forms
04/03/2003CA2461865A1 Dosage form containing a confectionery composition
04/03/2003CA2461709A1 Small organic molecule regulators of cell proliferation
04/03/2003CA2461684A1 Modified release dosage forms
04/03/2003CA2461682A1 Composite dosage forms
04/03/2003CA2461666A1 Combination therapies for immune mediated diseases
04/03/2003CA2461656A1 Modified release dosage forms
04/03/2003CA2461653A1 Edible composition and dosage form comprising an edible shell
04/03/2003CA2461616A1 Composite dosage forms having an inlaid portion
04/03/2003CA2461142A1 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
04/03/2003CA2460953A1 Proteins associated with cell growth, differentiation, and death
04/03/2003CA2447984A1 Dosage forms having an inner core and outer shell with different shapes
04/03/2003CA2446760A1 Dosage forms having an inner core and outer shell
04/03/2003CA2446759A1 Modified release dosage forms
04/02/2003EP1298206A1 Use of the Factor VII-activating protease for prevention and therapy of vaso-proliferative disorders
04/02/2003EP1297837A1 Remedies for allergic diseases and process for producing the same
04/02/2003EP1297152A2 Isolated human aminotransferase proteins, nucleic acid molecules encoding human aminotransferase proteins, and uses thereof
04/02/2003EP1297137A2 Gp286 nucleic acids and polypeptides
04/02/2003EP1297135A2 Pd-l2 molecules: novel pd-1 ligands and uses therefor
04/02/2003EP1297116A2 Method for isolating and purifying a protein and resulting protein
04/02/2003EP1297017A2 Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
04/02/2003EP1297014A2 Transporters and ion channels
04/02/2003EP1297007A2 Mammalian protein phosphatases
04/02/2003EP1296996A1 Purine derivatives
04/02/2003EP1296990A2 Dihydropyridine compounds for the inhibition of calcium-influx
04/02/2003EP1296981A2 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
04/02/2003EP1296978A2 N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
04/02/2003EP1296972A1 Arylmethylamine derivatives for use as tryptase inhibitors
04/02/2003EP1296961A1 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists
04/02/2003EP1296956A1 Compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors
04/02/2003EP1296949A2 Piperidine amides as modulators of chemokine receptor activity
04/02/2003EP1296943A1 Amino acid derivatives and their use as medicines
04/02/2003EP1296929A2 Modified forms of pharmacologically active agents and uses therefor
04/02/2003EP1296923A2 Aspirin-triggered lipid mediators
04/02/2003EP1296709A1 Solubilised protein vaccines
04/02/2003EP1296708A1 Use of secretin-receptor ligands in treatment of cystic fibrosis (cf) and chronic obstructive pulmonary disease (copd)
04/02/2003EP1296699A1 Therapeutic agents - iii
04/02/2003EP1296698A1 Therapeutic agents - ii
04/02/2003EP1296697A1 Therapeutic agents - i
04/02/2003EP1296693A1 Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor.
04/02/2003EP1296683A2 Methods of treating neutrophil-related diseases with topical anesthetics
04/02/2003EP1296670A1 Therapeutic combinations of fatty acids
04/02/2003EP1296651A1 Method of making particles for use in a pharmaceutical composition
04/02/2003EP1296552A2 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5
04/02/2003EP1226143B1 Imidazopyridine derivatives used as phosphodiesterase vii inhibitors
04/02/2003EP1208100B1 Selective antagonists of a2b adenosine receptors
04/02/2003EP1114051B1 INHIBITORS OF p38
04/02/2003EP1083886B1 Drug delivery system comprising a tightly compacted solid medicament stock
04/02/2003EP0954519B1 Alpha-9 integrin antagonists and anti-inflammatory compositions therof
04/02/2003EP0934320B1 Naphthyridine derivatives
04/02/2003EP0770081B1 Heterocycle-condensed morphinoid derivatives
1 ... 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 ... 878